Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3–9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is lim...

Descripción completa

Detalles Bibliográficos
Autores principales: Almeida, Antonio M., Prebet, Thomas, Itzykson, Raphael, Ramos, Fernando, Al-Ali, Haifa, Shammo, Jamile, Pinto, Ricardo, Maurillo, Luca, Wetzel, Jaime, Musto, Pellegrino, Van De Loosdrecht, Arjan A., Costa, Maria Joao, Esteves, Susana, Burgstaller, Sonja, Stauder, Reinhard, Autzinger, Eva M., Lang, Alois, Krippl, Peter, Geissler, Dietmar, Falantes, Jose Francisco, Pedro, Carmen, Bargay, Joan, Deben, Guillermo, Garrido, Ana, Bonanad, Santiago, Diez-Campelo, Maria, Thepot, Sylvain, Ades, Lionel, Sperr, Wolfgang R., Valent, Peter, Fenaux, Pierre, Sekeres, Mikkael A., Greil, Richard, Pleyer, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412421/
https://www.ncbi.nlm.nih.gov/pubmed/28420120
http://dx.doi.org/10.3390/ijms18040837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412421/
https://www.ncbi.nlm.nih.gov/pubmed/28420120
http://dx.doi.org/10.3390/ijms18040837

Ejemplares similares